NEW YORK, NY / ACCESSWIRE / August 19, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Anheuser-Busch Inbev Sa/Nv (BUD)
Lawsuit on behalf of: Investors who purchased March 1, 2018 - October 24, 2018
Lead Plaintiff Deadline: August 20, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anheuser-busch-inbev-sa-nv-loss-form?prid=3059&wire=1
According to the filed complaint, Defendants issued a steady stream of materially false and misleading reassurances about Anheuser Busch’s deleveraging efforts, cost cutting measures, EBITDA growth, the sufficiency of its liquidity and its debt maturity profile during the Class Period. These positive statements by Defendants created a false impression and materially misled investors about the Company’s finances, including the sustainability of Anheuser-Busch’s dividends. Once Defendants chose to speak about Anheuser-Busch’s finances, they had a duty to speak completely and truthfully, including speaking about those factors that were then having a material adverse effect on the Company’s deleveraging efforts.
Teva Pharmaceutical Industries Ltd. (TEVA)
Lawsuit on behalf of: Investors who purchased on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares (“ADS”) between August 4, 2017 and May 10, 2019
Lead Plaintiff Deadline: August 23, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/teva-pharmaceutical-industries-ltd-loss-form?prid=3059&wire=1
According to the filed complaint, (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.
Verb Technology Company, Inc. (f/k/a nFüsz, Inc.) (VERB)
Lawsuit on behalf of: Investors who purchased January 3, 2018 - May 2, 2018
Lead Plaintiff Deadline: September 9, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/verb-technology-company-inc-f-k-a-nfusz-inc-fusz-loss-form?prid=3059&wire=1
The filed complaint alleges that Verb Technology Company, Inc. (f/k/a nFüsz, Inc.) violated federal securities laws by issuing materially false and/or misleading information and/or failing to disclose material information. Specifically, Defendants made false and/or misleading statements as to the scope of the Agreement with Oracle as the Company did not have a contract with Oracle to jointly develop and market the Company’s product and that as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: